› $150,000,000 verdict in personal injury case
A decrease in reported cases of breast cancer across the country linked to the decline of hormone replacement therapy (HRT) is more significant in affluent, urban areas, according to a study published in the journal BMC Medicine.
Researchers in Ottawa, Canada are hoping to ease women’s fear of hormone replacement drugs by creating and testing synthetic hormones to combat aggravating symptoms of menopause, according to Canada.com. The research follows an earlier grant from the Canadian Breast Cancer Foundation to explore the re-engineering of estrogen estradiol, which is one of the components of the popular hormone replacement therapy (HRT) Premarin. The new grant, funded by a $267,000 research grant from the Canadian Breast Cancer Foundation, seeks to evaluate those compounds of synthesized molecules on the liver, cardiac and other types of cells. The goal is that it must relieve menopausal symptoms while not promoting breast or uterine cancer.
Women who took Wyeth’s hormone replacement therapy (HRT) Prempro at least five years are at greater risk of dying from non-small cell lung cancer, according to a recent study presented at an American Society of Clinical Oncology meeting.
Women on hormone replacement therapy (HRT) who have no family history of breast cancer have the same risk of developing breast cancer as women with a family history who are on HRT, according to a University of Rochester Medical Center Study.
A new study published this week in the New England Journal of Medicine suggests a sudden decrease in breast cancer in several countries worldwide is likely linked to the 2002 Women’s Health Initiative (WHI) finding that hormone replacement therapy (HRT) after menopause can dramatically increase a woman’s risk of breast cancer and other serious health problems, the Wall Street Journal reports.
Hormone replacement therapy (HRT) and its link to breast cancer and other serious conditions continue to make headlines. This week, U.S. News & World Report announced that women who take HRT and then get breast cancer are at lower risk of dying from their disease, according to a new study by the University of California-Irvine.
A study in the Journal of the American Medical Association (JAMA) reveals that women who took hormone replacement therapy (HRT) face an increased risk of cancer several years after stopping the treatment, according to an NPR report.
Women with existing heart conditions should consider their heart disease risk and visit a doctor for a heart health evaluation when considering estrogen hormone replacement therapy (HRT), according to a University of Michigan study.
Women who take breast cancer drugs Arimidex or generic tamoxifen and suffer with menopausal symptoms such as hot flashes, night sweats or painful joints may be less likely to have a reoccurrence of their cancer tumors, according to Reuters.
Wyeth, the pharmaceutical company that makes hormone replacement therapies Prempro and Premarin, announced today that it is ending its research in its signature areas of contraceptives and menopause treatments to focus on other female problems such as ovarian and breast cancers, according to the Associated Press/Washington Post.
